|1.||Hou, Ming-Hon: 2 articles (01/2012 - 06/2009)|
|2.||Yuann, Jeu-Ming P: 2 articles (01/2012 - 06/2009)|
|3.||Liu, Hong: 2 articles (04/2003 - 01/2003)|
|4.||Chen, Wei R: 2 articles (04/2003 - 01/2003)|
|5.||Ishmael, D Richard: 2 articles (04/2003 - 01/2003)|
|6.||Nordquist, Robert E: 2 articles (04/2003 - 01/2003)|
|7.||Samoylenko, O: 1 article (12/2015)|
|8.||Karnaushenko, O V: 1 article (12/2015)|
|9.||Gulua, L: 1 article (12/2015)|
|10.||Turmanidze, T: 1 article (12/2015)|
03/01/1986 - "Some aspects of clearance of mitoguazone in cancer patients and experimental cancer models."
12/01/1988 - "In vitro studies demonstrate the accumulation of tumor cells exposed to mitoguazone in S- and G2-phases of the cell cycle. "
04/01/1986 - "Phase II evaluation of mitoguazone in cancers of the esophagus, stomach, and pancreas: a Southeastern Cancer Study Group Trial."
06/01/1985 - "The present study examines whether this phenomenon is related to a DFMO-mediated increase in the selectivity of MGBG for tumor tissue. "
01/01/1985 - "[Phase II trial of mitoguazone in patients with recurrent extensive cervicofacial tumors]."
01/01/1988 - "After the first dose of MGBG there was an increase in polyamine content in the mononuclear cells of both the peripheral blood and the bone marrow despite the administration of DFMO in all patients with leukemia. "
02/01/1983 - "Combined use of 2-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) in normal and leukemia-bearing mice."
08/04/1982 - "Indirect determination of methylglyoxal bis(guanylhydrazone) in leukocytes of leukemia patients."
05/01/1981 - "MGBG labeled with 14C in the guanylhydrazone moiety was administered i.v. (150 microCi; specific activity, 1.9 microCi/mumol; 20 mg total) to six patients with leukemia. "
05/01/1981 - "Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia."
12/01/1982 - "Thirty-four assessable patients with advanced squamous cell and adenocarcinoma of the lung were treated with weekly MGBG in a phase II trial. "
12/01/1982 - "Phase II trial of methyl-GAG (NSC-32946) in squamous cell and adenocarcinoma of the lung."
01/01/1981 - "Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma."
01/01/1983 - "Simultaneous administration of both DFMO and MGBG affected the growth of renal adenocarcinoma less than did administration of DFMO or MGBG alone. "
12/01/1982 - "It would appear that MGBG does not have sufficient antitumor activity to warrant further investigation in advanced squamous cell and adenocarcinoma of the lung."
|4.||Psoriasis (Pustulosis Palmaris et Plantaris)
11/01/1983 - "These studies suggest that this topical MGBG formulation may be a candidate for use in the treatment of psoriasis and other hyperproliferative cutaneous diseases associated with increased polyamine synthesis."
12/01/1985 - "The simultaneous topical administration of DFMO and MGBG, allowing the use of lower concentrations of the more toxic MGBG, may be useful for therapy of psoriasis and other cutaneous disorders associated with abnormalities in polyamine metabolism."
11/01/1983 - "Topical methylglyoxal bis(guanylhydrazone) (MGBG) previously has been shown to produce partial clinical improvement in psoriasis. "
12/01/1985 - "Topical methylglyoxal bis(guanylhydrazone) (MGBG) and alpha-difluoromethylornithine (DFMO) individually have been shown to produce partial clinical improvement in psoriasis. "
03/01/1997 - "Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de novo recurrent lymphoma. "
04/01/1982 - "MGBG has significant antineoplastic activity against lymphomas, with 16/40 heavily pretreated patients (40%) having partial remissions (PR) lasting 1 to 8+ months. "
06/01/1981 - "We conclude that methyl-GAG has major antitumor activity when administered on this schedule to patients with advanced malignant lymphoma. "
06/01/1981 - "The low degree of toxicity, unique mechanism of action, and minimal myelosuppressive effects suggest that methyl-GAG will prove useful in future trials of combination chemotherapy regimens for the treatment of lymphoma."
03/01/1997 - "The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. "
|7.||Vinblastine (Vinblastine Sulfate)
|8.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Transplantation (Transplant Recipients)